Autopsy report · NCT00644878

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

“Slower than expected enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 5 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 9 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Interventions

Nilotinib

Participants

18

Sites

11

Countries

United States

Trials that died the same way

• Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
  “Slower than anticipated enrollment” (98% match in meaning)
• Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
  “Slow rate of enrollment” (92% match in meaning)
• A Study of T2000 in Essential Tremor
  “Slow enrollment” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.